急性淋巴细胞白血病患者后续聚乙二醇门冬酰胺酶失活的早期预测——一项NOPHO ALL2008研究
该研究基于NOPHO ALL2008方案纳入644例1-45岁急性淋巴细胞白血病患者,分析3003份聚乙二醇门冬酰胺酶酶活性样本,失活发生率为15.2%。药代动力学模型检测失活患者清除率升高的敏感性为87.8%、特异性为65.5%,提示药代动力学采样可能预测失活并在临床表现前及时干预。
要点
- 聚乙二醇门冬酰胺酶失活发生率为15.2%,药代动力学模型检测清除率升高的敏感性87.8%、特异性65.5%。
- 药代动力学采样可能预测失活,并在临床表现前实现及时干预。
- 需进一步完善模型并将其他方案纳入统一模型。
核心结论
- 在NOPHO ALL2008数据集中识别出失活前清除率升高,提示药代动力学采样可能预测失活并在临床表现前及时干预。
- 进一步优化并将其他方案纳入统一模型,有望提高临床医生评估个体患者风险的能力。
研究设计与样本
- 研究覆盖644例1-45岁急性淋巴细胞白血病患者,采用NOPHO ALL2008方案,于2017年2月至2022年12月在北欧和波罗的海国家开展,共纳入3003份聚乙二醇门冬酰胺酶酶活性样本。
- 采样的时间为聚乙二醇门冬酰胺酶给药后14天,并在给药间期额外采样。
主要发现
- 失活发生率为15.2%。
- 利用药代动力学模型,在发生失活的患者中检测聚乙二醇门冬酰胺酶清除率随时间升高的敏感性为87.8%,特异性为65.5%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polyethylene glycol (peg)-asparaginase plays a crucial role in acute lymphoblastic leukaemia (ALL) treatment, yet its associated toxicity often leads to treatment discontinuation, elevating relapse risk. Hypersensitivity with inactivation of asparaginase is common and often associated with severe allergic reactions. This study aims to comprehensively analyse asparaginase enzyme activity (AEA) pharmacokinetics, validate a previously developed pharmacokinetic model based on intravenous administration and evaluate its capability to detect changes in clearance before inactivation in patients treated with intramuscular peg-asparaginase. The study, covering 644 patients aged 1-45 with ALL under the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 Protocol (February 2017-December 2022, in Nordic and Baltic countries), included 3003 AEA samples. Sampling occurred 14 days post peg-asparaginase doses, with additional sampling between doses. The incidence of inactivation was 15.2%. Utilizing the pharmacokinetic model, estimates revealed an 87.8% sensitivity and 65.5% specificity for detecting increased peg-asparaginase clearance over time in patients experiencing inactivation. Identification of increased clearance preceding inactivation in the NOPHO ALL2008 dataset highlights the potential of pharmacokinetic sampling to predict inactivation and enable timely intervention before clinical manifestation, with further refinement and inclusion of additional protocols into a unified model offering the promise of improving clinicians' ability to assess individual patient risk.
引用
- Dam M, Centanni M, Centanni D, et al. Early prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study. Br J Haematol. 2025. PMID: 40916350. doi:10.1111/bjh.70145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。